Our microbial cotravelers have increasingly apparent roles in both maintaining health and causing disease in several organ systems. Investigators gather annually at the National Institutes of Health to present new discoveries regarding the role of the microbiome in human health and a special focus on persons living with HIV. Here, we summarize the discussions from the third annual Virology Education workshop on the microbiome in HIV, which took place in October of 2017.
Get full access to this article
View all access options for this article.
References
1.
HendersonWA, Rahim-WilliamsB, KimKH, et al.: The gastrointestinal pain pointer: A valid and innovative method to assess gastrointestinal symptoms. Gastroenterol Nurs, 2017; 40:357–363.
2.
FourieNH, WangD, AbeySK, et al.: The microbiome of the oral mucosa in irritable bowel syndrome. Gut Microbes, 2016; 7:286–301.
3.
FourieNH, WangD, AbeySK, et al.: Structural and functional alterations in the colonic microbiome of the rat in a model of stress induced irritable bowel syndrome. Gut Microbes, 2017; 8:33–45.
4.
TenorioAR, ZhengY, BoschRJ, et al.: Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis, 2014; 210:1248–1259.
5.
Noguera-JulianM, RocafortM, GuillénY, et al.: Gut microbiota linked to sexual preference and HIV infection. EBioMedicine, 2016; 5:135–146.
6.
LiuJ, WilliamsB, FrankD, DillonSM, WilsonCC, LandayAL: Inside out: HIV, the gut microbiome, and the mucosal immune system. J Immunol, 2017; 198:605–614.
7.
KlaseZ, OrtizA, DeleageC, et al.: Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol, 2015; 8:1009–1020.
8.
StefkaAT, FeehleyT, TripathiP, et al.: Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci U S A, 2014; 111:13145–13150.
9.
DillonSM, KibbieJ, LeeEJ, et al.: Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS, 2017; 31:511–521.
10.
DillonSM, CastlemanMJ, FrankDN, et al.: Brief report: Inflammatory colonic innate lymphoid cells are increased during untreated HIV-1 infection and associated with markers of gut dysbiosis and mucosal immune activation. J Acquir Immune Defic Syndr, 2017; 76:431–437.
11.
TangWH, WangZ, LevisonBS, et al.: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med, 2013; 368:1575–1584.
12.
SiednerMJ, KimJ-H, NakkuRS, et al.: Persistent immune activation and carotid atherosclerosis in HIV-infected ugandans receiving antiretroviral therapy. J Infect Dis, 2016; 213:370–378.
13.
Vujkovic-CvijinI, DunhamRM, IwaiS, et al.: Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med, 2013; 5:193ra91.
14.
CassolE, MisraV, HolmanA, KamatA, MorgelloS, GabuzdaD: Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis, 2013; 13:203.
15.
QiQ, HuaS, ClishCB, et al.: Plasma tryptophan-kynurenine metabolites are altered in HIV infection and associated with progression of carotid artery atherosclerosis. Clin Infect Dis, 2018; 67:235–242.
16.
FuJ, BonderMJ, CenitMC, et al.: The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res, 2015; 117:817–824.
17.
BeluryMA, BowmanE, GabrielJ, et al.: Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV. Pathog Immun, 2017; 2:376–403.
18.
NeufeldKM, KangN, BienenstockJ, FosterJA: Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil, 2011; 23:255–264, e119.
19.
CarlsonAL, XiaK, Azcarate-PerilMA, et al.: Infant gut microbiome associated with cognitive development. Biol Psychiatry, 2018; 83:148–159.
20.
BajajJS, IdilmanR, MabudianL, et al.: Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology, 2018; 68:234–247.
GarridoD, Ruiz-MoyanoS, KirmizN, et al.: A novel gene cluster allows preferential utilization of fucosylated milk oligosaccharides in Bifidobacterium longum subsp longum SC596. Sci Rep, 2016; 6:35045.
23.
DavisJCC, TottenSM, HuangJO, et al.: Identification of oligosaccharides in feces of breast-fed infants and their correlation with the gut microbial community. Mol Cell Proteomics, 2016; 15:2987–3002.
24.
HudaMN, LewisZ, KalanetraKM, et al.: Stool microbiota and vaccine responses of infants. Pediatrics, 2014; 134:e362–ee372.
25.
UnderwoodMA, GaerlanS, De LeozMLA, et al.: Human milk oligosaccharides in premature infants: Absorption, excretion, and influence on the intestinal microbiota. Pediatr Res, 2015; 78:670–677.
26.
ToskaE, PantelicM, MeinckF, KeckK, HaghighatR, CluverL: Sex in the shadow of HIV: A systematic review of prevalence, risk factors, and interventions to reduce sexual risk-taking among HIV-positive adolescents and youth in sub-Saharan Africa. PLoS One, 2017; 12:e0178106.
27.
Abdool KarimQ, Abdool KarimSS, FrohlichJA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329:1168–1174.
28.
KlattNR, CheuR, BirseK, et al.: Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science, 2017; 356:938–945.
29.
MassonL, PassmoreJA, LiebenbergLJ, et al.: Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis, 2015; 61:260–269.
30.
GosmannC, AnahtarMN, HandleySA, et al.: Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity, 2017; 46:29–37.
31.
RavelJ, GajerP, AbdoZ, et al.: Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A, 2011; 108Suppl 1:4680–4687.
32.
AnahtarMN, ByrneEH, DohertyKE, et al.: Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity, 2015; 42:965–976.
33.
FettweisJM, BrooksJP, SerranoMG, et al.: Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology, 2014; 160:2272–2282.
34.
WesselsJM, LajoieJ, VitaliD, et al.: Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of Lactobacillus. PLoS One, 2017; 12:e0187612.
35.
AldunateM, TyssenD, JohnsonA, et al.: Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother, 2013; 68:2015–2025.
36.
GraverMA, WadeJJ: The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal Lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob, 2011; 10:8.
37.
HearpsAC, TyssenD, SrbinovskiD, et al.: Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol, 2017; 10:1480–1490.
38.
BradshawCS, PirottaM, De GuingandD, et al.: Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: Randomised placebo-controlled double-blind trial. PLoS One, 2012; 7:e34540.
39.
WoodmanZ: Can one size fit all? Approach to bacterial vaginosis in sub-Saharan Africa. Ann Clin Microbiol Antimicrob, 2016; 15:16.
40.
BelkaidY, HandTW: Role of the microbiota in immunity and inflammation. Cell, 2014; 157:121–141.
41.
OhJZ, RavindranR, ChassaingB, et al.: TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity, 2014; 41:478–492.
42.
KimD, KimYG, SeoSU, et al.: Corrigendum: Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin. Nat Med, 2016; 22:961.
43.
HarrisVC, ArmahG, FuentesS, et al.: Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J Infect Dis, 2017; 215:34–41.
44.
RoutyB, Le ChatelierE, DerosaL, et al.: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2018; 359:91–97.
45.
WilliamsWB, LiaoHX, MoodyMA, et al.: HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015; 349:aab1253.
46.
FouratiS, CristescuR, LobodaA, et al.: Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun, 7:10369.
47.
RocaCS, HiraoLA, et al.: Subclinical cytomegalovirus infection is associated with altered host immunity, gut microbiota, and vaccine responses. J Virol, 2018. DOI: 10.1128/JVI.00167-18.
